Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Stuve

Showing results (21-30 of 88) with videos related to

Pageof 9
Sort By:
Therapeutic Advances in Neurological Disorders|July 24, 2018
Clinical trials in multiple sclerosis: milestonesYinan Zhang, Amber Salter, Gary Cutter, et al.
Neurology India|May 8, 2015
Spinal gout: A rare cause of paraplegiaDivyanshu Dubey, Emily Steen, Anshudha Sawhney, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 22, 2020
Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting DatabaseNatalia Gonzalez Caldito, Afsaneh Shirani, Amber Salter, et al.
Expert Review of Clinical Immunology|December 20, 2014
Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the futureItay Raphael, Johanna Webb, Olaf Stuve, et al.
Expert Review of Neurotherapeutics|May 13, 2016
Diagnostic and therapeutic strategies for management of autoimmune encephalopathiesDivyanshu Dubey, Kyle Blackburn, Benjamin Greenberg, et al.
BMC Neurology|January 1, 2015
Heat exposure and bicycling trigger recurrent aseptic meningitis: a case reportOlaf Stuve, Ellen Marder, Annette Okai, et al.
Neuroimaging Clinics of North America|December 11, 2008
Immunologic mechanisms of multiple sclerosisElliot M Frohman, Todd Eagar, Nancy Monson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 28, 2022
T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapyAnthony T Reder, Olaf Stuve, Stephanie K Tankou, et al.
Plos One|February 12, 2020
Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patientsMyla D Goldman, Lauren Dwyer, Rachael Coleman, et al.
Therapeutic Advances in Neurological Disorders|July 11, 2020
Diclofenac reduces the risk of Alzheimer's disease: a pilot analysis of NSAIDs in two US veteran populationsOlaf Stuve, Rick A Weideman, Danni M McMahan, et al.
Pageof 9

Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Therapeutic Advances in Neurological Disorders|July 24, 2018
Clinical trials in multiple sclerosis: milestonesYinan Zhang, Amber Salter, Gary Cutter, et al.
Neurology India|May 8, 2015
Spinal gout: A rare cause of paraplegiaDivyanshu Dubey, Emily Steen, Anshudha Sawhney, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 22, 2020
Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting DatabaseNatalia Gonzalez Caldito, Afsaneh Shirani, Amber Salter, et al.
Expert Review of Clinical Immunology|December 20, 2014
Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the futureItay Raphael, Johanna Webb, Olaf Stuve, et al.
Expert Review of Neurotherapeutics|May 13, 2016
Diagnostic and therapeutic strategies for management of autoimmune encephalopathiesDivyanshu Dubey, Kyle Blackburn, Benjamin Greenberg, et al.
BMC Neurology|January 1, 2015
Heat exposure and bicycling trigger recurrent aseptic meningitis: a case reportOlaf Stuve, Ellen Marder, Annette Okai, et al.
Neuroimaging Clinics of North America|December 11, 2008
Immunologic mechanisms of multiple sclerosisElliot M Frohman, Todd Eagar, Nancy Monson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 28, 2022
T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapyAnthony T Reder, Olaf Stuve, Stephanie K Tankou, et al.
Plos One|February 12, 2020
Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patientsMyla D Goldman, Lauren Dwyer, Rachael Coleman, et al.
Therapeutic Advances in Neurological Disorders|July 11, 2020
Diclofenac reduces the risk of Alzheimer's disease: a pilot analysis of NSAIDs in two US veteran populationsOlaf Stuve, Rick A Weideman, Danni M McMahan, et al.
Pageof 9